PRO 140

From Wikipedia, the free encyclopedia

PRO 140 is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of HIV infection.[1]

The United States Food and Drug Administration has designated PRO 140 for fast-track approval.[2]

Contents

[edit] Development

PRO 140 is being developed by Progenics Pharmaceuticals. In May 2007, they announced results from the phase I clinical trial of the drug. The researchers said the results demonstrated "potent, rapid, prolonged, dose-dependent, highly significant antiviral activity" for PRO 140. Participants in the highest dosing group received 5mg/kg and showed an average viral load decrease of -1.83 log10. On average, reductions of greater than -1 log10 copies/ml were maintained for between two and three weeks, from only a single dose of the drug.[3] The largest individual HIV RNA reductions ranged up to -2.5 log10 among patients receiving both the 2 and 5 mg/kg doses.[4]

[edit] Mechanism of Action

PRO 140 functions as an entry inhibitor.[5] PRO 140 binds to the CCR5 receptor, and interferes with HIV's ability to enter the cell. Unlike other entry inhibitors, PRO 140 is a monoclonal antibody. As such, it must be injected to be effective. However, once inside the body, PRO 140 binds to to CCR5 for >60 days,[1] which may allow for dosing as infrequently as every other week.[6][7]

[edit] External links

Animation of PRO 140 mechanism

[edit] References

  1. ^ a b Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation. Press release, 22 Feb 2006. Progenics Pharmaceuticals.
  2. ^ Brian Lawler. Progenics' Intriguing Study Results. The Motley Fool. 2 May 2007.
  3. ^ Derek Thaczuk. ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody. AIDSmap.com. 21 Sept 2007.
  4. ^ Liz Highleyman. Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study. 28 Sept 2007. HIVandHepatitis.com
  5. ^ Biswas P, Tambussi G, Lazzarin A (2007). "Access denied? The status of co-receptor inhibition to counter HIV entry". Expert Opin Pharmacother 8 (7): 923–33. doi:10.1517/14656566.8.7.923. PMID 17472538. 
  6. ^ PRO 140. Progenics Pharmaceuticals.
  7. ^ Tim Horn. Single-Dose PRO 140 Has Lasting Effects. 21 Sept 2007. POZ.com.
Pills  This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.


v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI)
Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI)
Protease Inhibitors (PI)
Entry/fusion inhibitors
Enfuvirtide • Maraviroc • Vicriviroc† • PRO 140† • Ibalizumab†
Integrase inhibitors
Maturation inhibitors
Bevirimat† • Vivecon™†
Combined formulations
Other &
experimental agents
°DHHS preferred first-line agent. †Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent. §Development terminated.
v • d • e
Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)
"-lizu-" (immune system)
"-bazu-" (bacterial)
"-cizu-" (cardiovascular)
"-neuzu-" (nervous system)
"-toxazu-" (toxin as target)
"-vizu-" (viral infections)